Tipranavir may increase the antiplatelet activities of Clopidogrel. The metabolism of Seratrodast can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Naftopidil. Clopidogrel may increase the anticoagulant activities of Certoparin. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine. The risk or severity of adverse effects can be increased when Rifapentine is combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Nadroparin. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ticlopidine resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Argatroban. Clopidogrel may increase the anticoagulant activities of Sulodexide. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rabeprazole resulting in a loss in efficacy. The metabolism of Enasidenib can be decreased when combined with Clopidogrel. Dasatinib may increase the anticoagulant activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Dextran 70. The risk or severity of adverse effects can be increased when Rifabutin is combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Telithromycin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Aprotinin. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Citalopram resulting in a loss in efficacy. The metabolism of Prasugrel can be decreased when combined with Clopidogrel. The serum concentration of Clopidogrel can be increased when it is combined with Palbociclib. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan. The metabolism of Clopidogrel can be decreased when combined with Atazanavir. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Moclobemide resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Isavuconazonium. The risk or severity of adverse effects can be increased when Rifaximin is combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Xylometazoline. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Balsalazide. The metabolism of Clopidogrel can be decreased when combined with Saquinavir. The metabolism of Clopidogrel can be decreased when combined with Ticagrelor. The risk or severity of adverse effects can be increased when Limaprost is combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nilvadipine. Ifetroban may increase the anticoagulant activities of Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Crisaborole. The metabolism of Clopidogrel can be decreased when combined with Tolbutamide. Erythromycin may decrease the antiplatelet activities of Clopidogrel. The metabolism of Clopidogrel can be increased when combined with Phenobarbital. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ziconotide. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Delavirdine resulting in a loss in efficacy. The serum concentration of Clopidogrel can be increased when it is combined with Simeprevir. The metabolism of Clobazam can be decreased when combined with Clopidogrel. Icosapent ethyl may increase the anticoagulant activities of Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Mexiletine. The serum concentration of Clopidogrel can be increased when it is combined with Ceritinib. The metabolism of Methadone can be decreased when combined with Clopidogrel. The serum concentration of Clopidogrel can be decreased when it is combined with Siltuximab. Glucosamine may increase the antiplatelet activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Lepirudin. Epoprostenol may increase the antiplatelet activities of Clopidogrel. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Methyl salicylate. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Carboxyamidotriazole. Clopidogrel may increase the anticoagulant activities of Eplivanserin. The serum concentration of Clopidogrel can be decreased when it is combined with Bosentan. The metabolism of Methyltestosterone can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Fondaparinux sodium. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amrinone. The metabolism of Testosterone can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Manidipine. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Darodipine. The metabolism of Clopidogrel can be increased when combined with Pentobarbital. Clopidogrel may increase the anticoagulant activities of Dabigatran etexilate. Clopidogrel may increase the anticoagulant activities of Dicoumarol. The serum concentration of Amodiaquine can be increased when it is combined with Clopidogrel. The metabolism of Brompheniramine can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Flunarizine. Clopidogrel may increase the anticoagulant activities of Desmoteplase. The metabolism of Clopidogrel can be decreased when combined with Thiotepa. The metabolism of Pethidine can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Anistreplase. The metabolism of Clopidogrel can be decreased when combined with Clarithromycin. Clopidogrel may increase the anticoagulant activities of Reteplase. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Trolamine salicylate. The metabolism of Mephenytoin can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Lidocaine. Clopidogrel may increase the anticoagulant activities of Protocatechualdehyde. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Luliconazole resulting in a loss in efficacy. The serum concentration of Clopidogrel can be increased when it is combined with Ranolazine. Clopidogrel may increase the anticoagulant activities of Warfarin. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Nitroaspirin. Clopidogrel may increase the anticoagulant activities of Tenecteplase. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lercanidipine. The metabolism of Clopidogrel can be increased when combined with Carbamazepine. The metabolism of Clopidogrel can be decreased when combined with Fluorouracil. The metabolism of Temazepam can be decreased when combined with Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Armodafinil resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Ozagrel. The serum concentration of Rosuvastatin can be increased when it is combined with Clopidogrel. The metabolism of Velpatasvir can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niguldipine. Treprostinil may increase the antiplatelet activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Selexipag. The metabolism of Clopidogrel can be decreased when combined with Caffeine. The metabolism of Clopidogrel can be decreased when combined with Fosamprenavir. The metabolism of Clopidogrel can be increased when combined with Secobarbital. The metabolism of Cisapride can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Vorapaxar. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Pantoprazole resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Leflunomide. Eptifibatide may increase the anticoagulant activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Triflusal. Clopidogrel may increase the anticoagulant activities of Fibrinolysin. The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Rivaroxaban. The metabolism of Clopidogrel can be decreased when combined with Venlafaxine. The metabolism of Halothane can be decreased when combined with Clopidogrel. The metabolism of Ifosfamide can be decreased when combined with Clopidogrel. Ketanserin may increase the anticoagulant activities of Clopidogrel. The metabolism of Epinastine can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Cyclosporine. Clopidogrel may increase the anticoagulant activities of Dextran. Ridogrel may increase the anticoagulant activities of Clopidogrel. The serum concentration of Conivaptan can be increased when it is combined with Clopidogrel. Relcovaptan may increase the anticoagulant activities of Clopidogrel. Andrographolide may increase the anticoagulant activities of Clopidogrel. The serum concentration of Clopidogrel can be increased when it is combined with Stiripentol. The metabolism of Clopidogrel can be decreased when combined with Capecitabine. The metabolism of Sevoflurane can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Pyrimethamine. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Topiramate resulting in a loss in efficacy. The metabolism of Tretinoin can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Sulfadiazine. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Mesalazine. The metabolism of Ethylmorphine can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Letaxaban. The metabolism of Clopidogrel can be decreased when combined with Sulfamethoxazole. The metabolism of Clopidogrel can be decreased when combined with Fluvastatin. The serum concentration of Clopidogrel can be decreased when it is combined with Deferasirox. Clopidogrel may increase the anticoagulant activities of Danaparoid. The metabolism of Methoxyflurane can be decreased when combined with Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Zucapsaicin resulting in a loss in efficacy.